Aspen Pharmacare agrees to US$220M Ovestin deal as it refocuses on emerging markets
Ennogen, which focuses on European markets, will acquire the rights and intellectual property, while Aspen will retain a manufacturing and supply role under long-term agreements.
SOUTH AFRICA – Aspen Pharmacare has agreed to sell the European commercialisation rights and related intellectual property for Ovestin, its women’s health medicine, to Ennogen Healthcare International for R3.66 billion (US$220 million).
The transaction also includes Ovestin-related inventory valued at €4 million (US$4.5 million), as the South African pharmaceutical group seeks to unlock value from non-core assets.
Ennogen, which focuses on European markets, will acquire the rights and intellectual property, while Aspen will retain a manufacturing and supply role under long-term agreements.
Under the arrangement, Aspen will manufacture and supply the active pharmaceutical ingredient and cream formulation of Ovestin in Europe for at least 10 years.
This will allow Ennogen to take responsibility for commercialisation while maintaining access to the product’s existing manufacturing and supply infrastructure.
Aspen will also provide strategic support services to Ennogen for five years at a monthly fee of €1 million (US$1.12 million).
In addition, the companies have agreed on transitional services for up to three years to facilitate the transfer of the business and support operational continuity.
Asset disposal supports portfolio realignment
The divestment forms part of Aspen’s strategy to realise value from assets outside its core focus on emerging markets.
The company will retain a role in Ovestin’s production through the supply agreements, allowing it to maintain manufacturing-related business while transferring European commercialisation responsibilities to Ennogen.
Ovestin generated revenue of R756 million (US$45.5 million) and profit after tax of R238 million (US$14.3 million) during Aspen’s 2026 financial year.
The figures highlight the product’s contribution to the group’s earnings and the financial significance of the disposal.
Aspen said it would allocate the transaction proceeds in line with its capital allocation strategy, with share buybacks remaining its preferred approach to returning capital to shareholders.
Ovestin’s role in women’s health
Ovestin is a prescription-only hormone therapy containing oestriol, a form of oestrogen used primarily to manage local menopausal symptoms.
Its European commercialisation rights will now move to Ennogen, while Aspen continues to manufacture and supply the medicine under the agreed arrangements.
The transaction separates the product’s commercial operations from its manufacturing activities, creating a long-term supply relationship between the two pharmaceutical companies.
It also gives Ennogen responsibility for developing Ovestin’s commercial presence in Europe while Aspen redirects capital towards its strategic priorities in emerging markets.
Be the first to leave a comment